Triton BioPharma AG
Research & Development Division
111 Grangeway Avenue, Suite 404
Toronto, Canada M1H 3E9
Phone: (416)289-0440 Fax: (416) 289-7440
www.tritonbiopharma.com

TRITON FELLOWSHIP PROGRAM: Pre- and post-doctoral fellowships supporting scaleable isolation, synthesis and in vivo evaluation of preclinical candidates for the control of neurological and neuropsychiatric disorders, cancer and infectious diseases.

Announcement Type: New

Request for Applications (RFA) Number: **RFA-Triton-08-05**

- **Key Dates**
  Release/Posted Date: April 25, 2008
  Application Due Date(s): May 19, 2008 (applications will be reviewed promptly as they arrive)
  Applicant Project Presentations: June 3 - 4, 2008
  Award notifications: June 5, 2008
  Earliest Anticipated Start Date(s): June 5, 2008

- **Funds Available and Anticipated Number of Awards.**
  Triton will make a commitment of up to USD $100,000 in total fellowship support for FY2008-2009, for pre- and post-doctoral research. Total pre-doctoral supplemental support will be in the range of $1,000-$15,000 per award and total post-doctoral support will range from $1,000-$25,000 per award based on experience and priority of the proposed project to Triton's development pipeline. Support under this fellowship program is contingent upon the availability of funds, the submission of a sufficient number of meritorious applications, and relevance to Triton's preclinical priorities (www.tritonbiopharma.com).

- **Budget and Project Period.**
  The total project period for an application submitted to this fellowship program may not exceed 1 year.

- **Eligible Pre- and Post-doctoral Candidates.**
  Students in all stages of Ph.D. research and early post-doctoral studies are eligible to apply.

I. Purpose

The purpose of Triton's Fellowship Program is to support and stimulate translational research leading to the development of novel and more effective interventions and research tools (e.g. natural product probes); to facilitate the production, and to promote the development, of novel therapeutics based on marine derived alkaloids, peptides and other marine natural products, which have promising activity in animal models, and are either part of Triton's licensed portfolio or have potential to be licensed to Triton BioPharma AG. For further information on Triton BioPharma AG and its research and development efforts, please visit our website at www.tritonbiopharma.com.

II. Application Submission Procedure

To submit an application to the Triton Fellowship Program, applicants must submit an Application Package via e-mail to **careers@tritonbiopharma.com** quoting "**RFA-Triton-08-05**" in the subject line. Applications must only be submitted electronically in Microsoft Word or PDF format**. PAPER APPLICATIONS WILL NOT BE ACCEPTED.**

The Application Package must include the following (*in Microsoft Word or PDF format*):

- 2 page NIH formatted curriculum vitae (students early in their career should include an NIH CV of their mentor)
- 2-3 page proposal describing the research project for funding

III. Application Processing

Applications **may** be submitted on or after the opening date and **must** be successfully received by Triton BioPharma AG no later than **5:00 p.m. E.S.T.** on the application due date. If an application is not submitted by the due date and time, the application may be delayed in the review process or not reviewed.

Once an application package has been successfully submitted via **careers@tritonbiopharma.com**, an acknowledgement of receipt will be sent via e-mail from Triton BioPharma AG. Applications will be evaluated for completeness and responsiveness by the Review Committee.

Note: ***Since email transmissions may be unreliable, it is the responsibility of the applicant to confirm successful submission in the event that no acknowledgement of receipt is received within 48 hours.***

IV. Funding Restrictions

All awards are subject to careful consideration and review, and will remain contingent upon the availability of funds, the submission of a sufficient number of meritorious applications, and relevance to Triton's preclinical priorities.

V. Review and Selection Process

Applicants may undergo 2 levels of review in the award selection, as described below:

1. *Preliminary Review*: Applications received that are complete and responsive to the Triton Fellowship Program objectives will undergo preliminary review of the scientific merit of the proposed research, as well as the relevance and potential significance to Triton's project priorities. Award selection will involve a critical review of the applicant's track record of research and/or industry experience, as supported by publications, presentations and patents.

2. *Project Presentations*: Applicants that are selected from the Preliminary Review will be required to prepare a PowerPoint presentation for submission to the Triton Fellowship Program Review Committee. The Review Committee will expect candidates to be available to present and defend their projects in front of the Committee (or by other means if attendance is impossible) on June 3 or June 4, 2008.

VI. Award Notices

A formal notification in the form of a Notice of Award will be provided to the applicant. Once all administrative and programmatic issues have been resolved, the Notice of Award will be generated via e-mail notification to the recipient.

The specific timelines, milestones and funding levels agreed by Triton BioPharma AG shall be included in the terms and conditions of the award. It is recognized that milestones and timelines may require revision and renegotiation during the course of the project period.

VII. Company Contacts

Inquiries concerning this supplemental funding opportunity regarding scientific/research programs or the review/selections process may be directed as below:

1. Scientific/Research Contacts:

Mark T. Hamann, Ph.D.
Chief Scientific Officer & Chief Operating Officer
Triton BioPharma AG
Telephone: (662) 915-5730
Email: mhamann@tritonbiopharma.com

2. Financial/Grants Management Contacts:

Vincent Ursini
Acting CFO, VP Mergers & Acquisitions
Triton BioPharma AG
Telephone: (601) 326-2272 ext. 225
Email: vursini@tritonbiopharma.com